Both authors contributed equally to the work.
Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000–2007
Version of Record online: 28 MAR 2012
© 2012 European Society of Clinical Microbiology and Infectious Diseases. No claim to original US government works
Clinical Microbiology and Infection
Volume 18, Issue 6, pages E185–E187, June 2012
How to Cite
De Castro, N., Mazoyer, E., Porcher, R., Raffoux, E., Suarez, F., Ribaud, P., Lortholary, O. and Molina, J.-M. (2012), Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000–2007. Clinical Microbiology and Infection, 18: E185–E187. doi: 10.1111/j.1469-0691.2012.03819.x
- Issue online: 14 MAY 2012
- Version of Record online: 28 MAR 2012
- Accepted manuscript online: 24 MAR 2012 04:44AM EST
- Original Submission: 13 October 2011; Revised Submission: 31 January 2012; Accepted: 5 February 2012 Editor: E. Roilides; Article published online: 24 March 2012
- 6Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813–1821., , et al.
- 20Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol 2010; 28: 1766–1771., , et al.